Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
Abivax presents first-half 2024 financial results
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
ABIVAX Société Anonyme (NASDAQ: ABVX) is now covered by analysts at Laidlaw. They set a "buy" rating and a $48.00 price target on the stock.